Cell and matrix interactions in diabetic vascular tissue engineering models
糖尿病血管组织工程模型中细胞和基质的相互作用
基本信息
- 批准号:9383944
- 负责人:
- 金额:$ 32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:Advanced Glycosylation End ProductsAffectAmericanAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsArterial Fatty StreakArteriesArtificial ImplantsAtherosclerosisBindingBiochemicalBiocompatible MaterialsBioreactorsBlood GlucoseBlood VesselsCaliberCardiovascular systemCellsChemicalsClinical ResearchCollagenCytoskeletonDepositionDevelopmentDevicesDiabetes MellitusDiseaseDyslipidemiasElastinEndothelial CellsEndotheliumEnvironmentEventExtracellular MatrixFibroblastsFibrosisFutureGlucoseGoalsGrowthHeart ValvesHumanHypertrophyImpaired wound healingImplantIncubatedInflammationInflammatory ResponseInjuryKidneyLightLinkLiteratureMechanicsMesenchymalMetforminModelingModificationMonitorMorphologyMyocardiumNADPH OxidaseNerveNude RatsOperative Surgical ProceduresOxidative StressPathologicPathologyPatientsPhysiologicalProblem SolvingProcessProductionProliferatingProteinsRattusReactive Oxygen SpeciesResistanceRisk FactorsRoleSmooth Muscle MyocytesStimulusTLR4 geneTestingTissue EngineeringTissuesTunica AdventitiaVascular DiseasesVascular remodelingabdominal aortabaseblood lipidcalcificationcardiovascular risk factorcell typecrosslinkdiabeticdiabetic patientemergency service responderexpectationhigh riskhuman tissueimmunoregulationimplantationinjuredinsulin sensitizing drugsmonocytenon-diabeticoxidationreceptorrepairedresponsescaffoldthree-dimensional modelingtissue support framevasa vasorumvascular tissue engineering
项目摘要
Diabetes is a major risk factor for vascular diseases that affects nearly all blood vessel types and
calibers. In diabetes, elevated levels of blood glucose and lipids interact irreversibly with long-lived
proteins, such as collagen and elastin from the blood vessel wall, via oxidation and crosslinking
processes, resulting in formation of advanced glycation end products (AGEs); the consequence is
vascular stiffening, the hallmark of diabetes. Furthermore, vascular cells respond to diabetes-
related altered environment by activation and leading to pathological remodeling and to the onset and
progression of vascular disease. Together, these severe cell and extracellular matrix (ECM) changes
result in activation of inflammation, impaired healing, fibrosis, and ectopic calcification.
The interaction of AGEs with their receptor, RAGE, stimulates the production of reactive oxygen
species, leading to dysfunctional remodeling of the vascular wall (stiffening, fibrosis, and calcification).
The goal of this project is to characterize the effect of diabetes on the adventitial fibroblasts and their
involvement in vascular pathology. By using 3D models based on tissue engineering principles, we
can control the type of cells seeded on a vascular matrix-based scaffold while providing the necessary
biochemical and mechanical stimuli in a physiologic bioreactor. The tissue engineered construct can
also be implanted in diabetic animal models, to explore the effect of ECM oxidation and AGE
accumulation on the fate of adventitial fibroblasts. The effect of antioxidant and anti-inflammatory
agents can also be monitored.
Our hypothesis is that fibroblasts are activated by ROS and contribute to the dysfunctional
remodeling of the vascular wall in response to diabetes-induced injuries. This hypothesis will be
tested in the following two aims.
In specific Aim 1 we will investigate the contribution of diabetic adventitial fibroblasts to the
pathological vascular wall remodeling. Vascular ECM-based scaffolds (acellular arteries) will be
seeded with human endothelial cells, smooth muscle cells, and fibroblasts and a) incubated in a
physiologic vascular bioreactor for 2 months in diabetic media, b) implanted as transposition grafts in
the abdominal aorta of normal and diabetic nude rats for 3 and 6 months. Grafts will be monitored for
oxidative stress and inflammation.
In specific Aim 2 we will explore the fate of diabetic adventitial fibroblasts in the presence of
antioxidant and anti-inflammatory agents. Vascular ECM-based scaffolds seeded with human
vascular cells will be a) incubated in a physiologic vascular bioreactor for 2 months in diabetic media
and b) implanted as transposition grafts in the abdominal aorta of normal and diabetic nude rats for 3
and 6 months, in the presence of antioxidant polyphenolic compounds, metformin, an insulin-
sensitizer drug, and immunomodulatory mesenchymal cells (in separate groups). Grafts will be
monitored for oxidative stress and inflammation.
Expectations: at the conclusion of this study, we would gain important information about the major
diabetes-related alterations in the vascular wall initiated by the adventitial fibroblasts, potentially
offering avenues for targeting these events.
糖尿病是血管疾病的主要危险因素,影响几乎所有血管类型和
口径。在糖尿病中,血糖和血脂水平升高与长寿不可逆地相互作用
通过氧化和交联产生蛋白质,例如血管壁中的胶原蛋白和弹性蛋白
过程,导致高级糖基化终产物(AGE)的形成;结果是
血管硬化,糖尿病的标志。此外,血管细胞对糖尿病有反应-
通过激活和导致病理重塑以及发病和发生相关改变的环境
血管疾病的进展。总之,这些严重的细胞和细胞外基质 (ECM) 变化
导致炎症激活、愈合受损、纤维化和异位钙化。
AGE 与其受体 RAGE 相互作用,刺激活性氧的产生
种,导致血管壁重塑功能失调(硬化、纤维化和钙化)。
该项目的目标是表征糖尿病对外膜成纤维细胞及其功能的影响
参与血管病理学。通过使用基于组织工程原理的 3D 模型,我们
可以控制接种在基于血管基质的支架上的细胞类型,同时提供必要的
生理生物反应器中的生化和机械刺激。组织工程构建体可以
也可植入糖尿病动物模型,探讨ECM氧化和AGE的影响
积累对外膜成纤维细胞命运的影响。抗氧化和抗炎作用
代理也可以被监控。
我们的假设是成纤维细胞被 ROS 激活并导致功能失调
血管壁重塑以应对糖尿病引起的损伤。这个假设将是
在以下两个目标中进行测试。
在具体目标 1 中,我们将研究糖尿病外膜成纤维细胞对糖尿病的贡献
病理性血管壁重塑。基于血管 ECM 的支架(无细胞动脉)将
接种人内皮细胞、平滑肌细胞和成纤维细胞,并且 a) 在
生理血管生物反应器在糖尿病培养基中培养 2 个月,b) 作为转位移植物植入
正常和糖尿病裸鼠的腹主动脉3个月和6个月。将监测移植物
氧化应激和炎症。
在具体目标 2 中,我们将探讨糖尿病外膜成纤维细胞在存在以下因素的情况下的命运:
抗氧化剂和抗炎剂。基于血管 ECM 的支架植入了人类
血管细胞将 a) 在生理血管生物反应器中的糖尿病培养基中孵育 2 个月
b) 将转位移植物植入正常和糖尿病裸鼠的腹主动脉 3 次
6 个月,在抗氧化剂多酚化合物二甲双胍(一种胰岛素)存在下
敏化剂药物和免疫调节间充质细胞(分在不同的组中)。移植物将是
监测氧化应激和炎症。
期望:在本研究结束时,我们将获得有关该专业的重要信息
由外膜成纤维细胞引发的与糖尿病相关的血管壁改变,可能
提供针对这些事件的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Agneta Simionescu其他文献
Agneta Simionescu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Agneta Simionescu', 18)}}的其他基金
Cell and matrix interactions in diabetic vascular tissue engineering models
糖尿病血管组织工程模型中细胞和基质的相互作用
- 批准号:
10227980 - 财政年份:2018
- 资助金额:
$ 32万 - 项目类别:
Cell and matrix interactions in diabetic vascular tissue engineering models
糖尿病血管组织工程模型中细胞和基质的相互作用
- 批准号:
9767842 - 财政年份:2018
- 资助金额:
$ 32万 - 项目类别:
相似国自然基金
基于lncRNA NONHSAT042241/hnRNP D/β-catenin轴探讨雷公藤衍生物(LLDT-8)对类风湿关节炎滑膜成纤维细胞功能影响及机制研究
- 批准号:82304988
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
针刺手法和参数对针刺效应启动的影响及其机制
- 批准号:82305416
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
二仙汤影响肾上腺皮质-髓质激素分泌及调控下丘脑温度感受器以缓解“天癸竭”潮热的研究
- 批准号:82374307
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
固定翼海空跨域航行器出水稳定性与流体动力载荷影响机制
- 批准号:52371327
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
经济制裁对跨国企业海外研发网络建构的影响:基于被制裁企业的视角
- 批准号:72302155
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of serum advanced glycation end-products in altering tendon properties with diabetes
血清晚期糖基化终末产物在改变糖尿病肌腱特性中的作用
- 批准号:
10737036 - 财政年份:2023
- 资助金额:
$ 32万 - 项目类别:
Dissecting connections between diet, the microbiome and Alzheimers disease
剖析饮食、微生物组和阿尔茨海默病之间的联系
- 批准号:
10740056 - 财政年份:2023
- 资助金额:
$ 32万 - 项目类别:
Project: Survivorship Care Physical Activity Initiative to Improve Disparities in HRQoL for Prostate Cancer Survivors (RELate Study)
项目:旨在改善前列腺癌幸存者 HRQoL 差异的生存护理体力活动计划(RELate 研究)
- 批准号:
10911646 - 财政年份:2023
- 资助金额:
$ 32万 - 项目类别:
Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy
Amadorins 作为糖尿病视网膜病变的新型口服疗法
- 批准号:
10601168 - 财政年份:2023
- 资助金额:
$ 32万 - 项目类别:
Quantifying the contribution of collagen cross-linking to increased bone fragility
量化胶原交联对骨脆性增加的贡献
- 批准号:
10303860 - 财政年份:2021
- 资助金额:
$ 32万 - 项目类别: